FindMyKOL
Clinical trialNCT00802815CompletedPhase Early 1Interventional

Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis

NCT00802815 is a phase early 1 interventional trial sponsored by Washington University School of Medicine. As of 21 Nov 2026, it is completed. It studies Etanercept in Inclusion Body Myositis. The registry lists an enrollment of 20 participants at 1 site in 1 country. The registry lists a start date of 30 Apr 2005 and a primary completion date of 31 May 2014.

SponsorWashington University School of Medicine →Enrollment20Inclusion Body Myositis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00802815
FieldValue
Registry IDNCT00802815
StatusCompleted
PhasePhase Early 1
Study typeInterventional trial
Lead sponsorWashington University School of Medicine
Enrollment20
Registered sites1
Countries1
ConditionsInclusion Body Myositis
DrugsEtanercept
Start30 Apr 2005
Primary completion31 May 2014
Study completion31 May 2014
Last update posted29 May 2014

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Inclusion body myositis (IBM) is the most common late onset acquired muscle disease. Patients develop progressive weakness that may result in the need for assistive devices including a wheelchair. IBM may be due to abnormal immune activation, due in part to overproduction of tumor necrosis factor (TNF)-alpha. Etanercept blocks the activity of TNF-alpha, thereby blunting immune overactivation. Previous unblinded studies and case reports suggest that etanercept may improve strength or slow the progressive weakness in IBM. We are conducting a double-blind, randomized, placebo-controlled study to test if Etanercept is beneficial in slowing the progressive weakness in patients with IBM.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Missouri, United States1 site
  • Washington University Department of Neurology

    St Louis

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouri: 1 siteMO1KentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00802815

Each answer restates registry values shown on this page.

What is NCT00802815?

NCT00802815 is a phase early 1 interventional trial sponsored by Washington University School of Medicine. It studies Etanercept in Inclusion Body Myositis.

Who leads NCT00802815?

The registry names Glenn Lopate, MD (principal investigator, Washington University School of Medicine) as the overall official.

Where does NCT00802815 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00802815 study?

The registered drug and biological interventions are Etanercept.

When did NCT00802815 end?

The registry lists a primary completion date of 31 May 2014 and a study completion date of 31 May 2014. The sponsor last updated the record on 29 May 2014.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.